Leerink Swann, a Massachusetts-based healthcare-focused US investment bank, has formed a global collaboration with Swiss company InterPharmaLink. The company claims that this enables Leerink Swann’s Strategic Advisory Group to access InterPharmaLink’s network and business platform in Europe and Japan.
InterPharmaLink is a provider of professional business development services to healthcare companies. It expects to gain in-depth insight into the US healthcare market through Leerink Swann’s business platform, following this collaboration.
Michael Jenkins, Senior Managing Director and Head of Leerink Swann Strategic Advisors, said: “InterPharmaLink’s principals have an extensive network and perennial professional experience in the pharmaceutical world, particularly in Europe and Japan, which are highly attractive markets for us.”
Raimund Eckel, CEO of InterPharmaLink, said: “Collaborating with Leerink Swann will enhance InterPharmaLink’s access to US healthcare companies and knowledge about the American pharma and biotech markets. This is a very important step for us and our global efforts in business development.”
Leerink Swann focuses on equity research, corporate finance, strategic advisory and asset management services for institutional, life sciences and high-net-worth clients. Through its MEDACorp division, it provides biomedical-consulting services to the institutional investment community. The Strategic Advisory Group at Leerink Swann provides advice to healthcare companies in areas including corporate strategy, therapeutic area strategy and specific product/device strategy.
